Saturday, May 19, 2018 9:37:37 AM
Now ALLAY has two powerful clinical trials with lots of real world data. So, it is next in line.
Read this very powerful PR from 2011, shown at the end, to understand the struggle BIEL went through with the FDA. All these products from Actipatch to RecoveryRx to ALLAY were supposed to be approved back in 2009-2010 timeframe.
Since then, the FDA learned a lot about the PEMF to the point where they had a special regulation in 2015 for short wave diathermy. The struggle that BIEL had with the FDA almost 10 years ago is paying off right now. It is going to be massive for the company, especially since everybody was banking that the company will go away and declare bankruptcy and its patented technology will be sold to major Pharma at the cheap. BIEL's survival over the years can be credited to the following:
a. BIEL's CEO Andy Whelan who is an astonishingly stubborn fighter that never let go. He believed deeply in the product and fought for the company's survival to the nth degree. He used every available option financial and technical to keep the company going. We have to give credits where credits due.
b. Investors like you and me and their deep believe in the company. A testament to that is the many posters you see on the IHUB board talking about Biel and defending the company.
c. This is to the surprise of many because so many people hate it, which is DILUTION. Remember that dilution is one of the mechanisms by which small pubic companies like BIEL survive until they become profitable. Contrary to so many people's belief, dilution is a must. If you don't use dilution you should not start a small public company. As a matter of fact, BIEL is the only company on the OTC that used dilution appropriately to continue their mission with the FDA and convince them that PEMF and the actipatch are good things and they work. In addition, they never performed a RS to cheat investors. Every investor knows the company AS and OS. RS is a tool used to lift the company to a higher exchange so it can tap into more investors. It should only be used for other purposes rarely and in extreme circumstances.
Believe it or not, both dilution and RS are two great ingredients to make a small public company successful as long a they are used for the intended purposes. The problem or the bad publicity for them stemmed from the fact that the majority of Pink OTC companies are scams and not controlled properly. They abuse both dilution and RS. It is your job as an investor to pick the good apple from the bad apple and there are many bad apples in the mix. BIEL is a Golden Apple. Investors should continue to invest in BIEL and support it. BIEL needs investors support.
http://www.marketwired.com/press-release/bioelectronics-files-fda-allay-therapy-response-provisional-patent-on-technology-pinksheets-biel-1546992.htm
Endexx Corporation (EDXC) Leverages Global Market Trends and Legislative Reforms to Spearhead Growth in the Cannabis and Plant-Based Wellness Sectors • EDXC • Mar 27, 2024 3:01 PM
Applied UV, Inc. Announces Pricing of $2.76 Million Registered Direct and Private Placement Priced at the Market Under Nasdaq Rules • AUVI • Mar 27, 2024 2:51 PM
POET and MultiLane Collaborate to Develop High-Speed Pluggable Transceivers for AI Networks • POET • Mar 27, 2024 10:52 AM
Maybacks Global Entertainment Opens 23 More Stations in Important Major Cities • AHRO • Mar 27, 2024 9:00 AM
NxGen Brands Inc. Forecast to Deliver 140% Growth in Q1 2024 • NXGB • Mar 27, 2024 7:30 AM
Kona Gold Beverages, Inc. Strategic Advancements: Covert LLC Introduces Federally Legal D9 Gummies and Revamps Innovative eCommerce Platform, Propelling Toward $12 Million Annual Revenue Goal • KGKG • Mar 26, 2024 8:30 AM